- Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform
- Essentially, NanoCelle delivers drug formulations via an oral spray
- So far, product testing results have indicated the spray can lead to better absorption of the drugs, helping the formulation avoid ingested routes
- It can also potentially lower drug dosages and reduce the side effects of some formulations
- Medlab has also filed patent applications in other jurisdictions, such as the U.S., Europe and New Zealand
- On the market this afternoon, Medlab is up 3.03 per cent, trading for 17 cents per share
Medlab Clinical: Recieves Australian patent for NanoCelle
